Hartmut Ruetten1, Mathias Gebauer1, Ralph H Raymond2, Roberto A Calle3, Claudio Cobelli4, Atalanta Ghosh5, R Paul Robertson6, Sudha S Shankar7, Myrlene A Staten8, Darko Stefanovski9, Adrian Vella10, Kathryn Wright11, David A Fryburg12. 1. 1 Sanofi-Aventis Deutschland GmbH , Frankfurt, Germany . 2. 2 R-Squared Solutions , Skillman New Jersey. 3. 3 Pfizer, Inc. , Cambridge, Massachusetts. 4. 4 Department of Information Engineering, University of Padova , Padova, Italy . 5. 5 Janssen Research and Development , Raritan, New Jersey. 6. 6 Pacific Northwest Diabetes Institute, University of Washington , Seattle, Washington. 7. 7 Lilly Research Laboratories, Lilly Corporate Center , Indianapolis, Indiana. 8. 8 NIDDK , Bethesda, Maryland. 9. 9 School of Veterinary Medicine, University of Pennsylvania , Philadelphia, Pennsylvania. 10. 10 Division of Endocrinology, Mayo Clinic and Foundation , Rochester, Minnesota. 11. 11 Wright Biomarker Consulting , Gales Ferry, Connecticut. 12. 12 ROI BioPharma Consulting , East Lyme, Connecticut.
Abstract
BACKGROUND: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion. METHODS: Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17), or with type 2 diabetes (T2DM, n = 22) were studied twice, following a mixed test meal (470 kCal) (mixed meal tolerance test [MMTT]) or intravenous L-arginine (arginine maximal stimulation test [AST], 5 g). GLP-1 (total and active), PYY, GIP, glucagon, and β cell function were measured before and following each stimulus. RESULTS: Baseline enteroendocrine hormones differed across the glucose tolerance (GT) spectrum, T2DM generally >NGT and PDM. In response to MMTT, total and active GLP-1, GIP, glucagon, and PYY increased in all populations. The incremental area-under-the-curve (0-120 min) of analytes like total GLP-1 were often higher in T2DM compared with NGT and PDM (35-51%; P < 0.05). At baseline glucose, L-arginine increased total and active GLP-1 and glucagon concentrations in all GT populations (all P < 0.05). As expected, the MMTT and AST provoked differential glucose, insulin, and C-peptide responses across GT populations. Baseline or stimulated enteroendocrine hormone concentrations did not consistently correlate with either measure of β cell function. CONCLUSIONS/ INTERPRETATION: Both MMTT and AST resulted in insulin and enteroendocrine hormone responses across GT populations without consistent correlation between release of incretins and insulin, which is in line with other published research. If a defect is in the enteroendocrine/β cell axis, it is probably reduced response to rather than diminished secretion of enteroendocrine hormones.
BACKGROUND: The aims of this study were to 1. define the responses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and peptide YY (PYY) to an oral meal and to intravenous L-arginine; and 2. examine correlation of enteroendocrine hormones with insulin secretion. We hypothesized a relationship between circulating incretin concentrations and insulin secretion. METHODS: Subjects with normal glucose tolerance (NGT, n = 23), prediabetes (PDM, n = 17), or with type 2 diabetes (T2DM, n = 22) were studied twice, following a mixed test meal (470 kCal) (mixed meal tolerance test [MMTT]) or intravenous L-arginine (arginine maximal stimulation test [AST], 5 g). GLP-1 (total and active), PYY, GIP, glucagon, and β cell function were measured before and following each stimulus. RESULTS: Baseline enteroendocrine hormones differed across the glucose tolerance (GT) spectrum, T2DM generally >NGT and PDM. In response to MMTT, total and active GLP-1, GIP, glucagon, and PYY increased in all populations. The incremental area-under-the-curve (0-120 min) of analytes like total GLP-1 were often higher in T2DM compared with NGT and PDM (35-51%; P < 0.05). At baseline glucose, L-arginine increased total and active GLP-1 and glucagon concentrations in all GT populations (all P < 0.05). As expected, the MMTT and AST provoked differential glucose, insulin, and C-peptide responses across GT populations. Baseline or stimulated enteroendocrine hormone concentrations did not consistently correlate with either measure of β cell function. CONCLUSIONS/ INTERPRETATION: Both MMTT and AST resulted in insulin and enteroendocrine hormone responses across GT populations without consistent correlation between release of incretins and insulin, which is in line with other published research. If a defect is in the enteroendocrine/β cell axis, it is probably reduced response to rather than diminished secretion of enteroendocrine hormones.
Authors: Christoffer Clemmensen; Sanela Smajilovic; Eric P Smith; Stephen C Woods; Hans Bräuner-Osborne; Randy J Seeley; David A D'Alessio; Karen K Ryan Journal: Endocrinology Date: 2013-08-19 Impact factor: 4.736
Authors: Galina Smushkin; Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad Journal: Diabetologia Date: 2008-11-27 Impact factor: 10.122
Authors: R Paul Robertson; Lindsey D Bogachus; Elizabeth Oseid; Susan Parazzoli; Mary Elizabeth Patti; Michael R Rickels; Christian Schuetz; Ty Dunn; Timothy Pruett; A N Balamurugan; David E R Sutherland; Gregory Beilman; Melena D Bellin Journal: Diabetes Date: 2014-09-03 Impact factor: 9.461
Authors: Sarah M Gray; Andrew L Hoselton; Radha Krishna; Cris A Slentz; David A D'Alessio Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Kamal Albarazanji; Andrea R Nawrocki; Bin Gao; Xiaoli Wang; Yixin Jim Wang; Yong-Fu Xiao Journal: Sci Rep Date: 2021-06-04 Impact factor: 4.379
Authors: Steven E Kahn; Kieren J Mather; Silva A Arslanian; Elena Barengolts; Thomas A Buchanan; Sonia Caprio; David A Ehrmann; Tamara S Hannon; Santica Marcovina; Kristen J Nadeau; Kristina M Utzschneider; Anny H Xiang; Sharon L Edelstein Journal: Diabetes Care Date: 2021-06-15 Impact factor: 17.152